Amplification of drug resistance against the background of inadequate chemotherapy for pulmonary tuberculosis
https://doi.org/10.21292/2075-1230-2019-97-8-46-51
Abstract
The article presents a clinical case of a patient with respiratory tuberculosis, who experienced the amplification of drug resistance against the background of inadequate chemotherapy for tuberculosis. It demonstrates the need for express drug susceptibility tests which allows timely prescription of the adequate regimen and thereby minimizing the chances of drug resistance amplification.
About the Authors
I. A. Burmistrova
National Medical Research Center of Phthisiopulmonology and Infectious Diseases
Russian Federation
Russian Federation
Irina A. Burmistrova ‒ Phthisiologist
4, Dostoevsky St., Moscow, 127473
E. V. Vaniev
National Medical Research Center of Phthisiopulmonology and Infectious Diseases
Russian Federation
Russian Federation
Eduard V. Vaniev ‒ Candidate of Medical Sciences, Head of Out-Patient Consulting Department
4, Dostoevsky St., Moscow, 127473
A. G. Samoylova
National Medical Research Center of Phthisiopulmonology and Infectious Diseases
Russian Federation
Russian Federation
Anastasiya G. Samoylova ‒ Doctor of Medical Sciences, Deputy Director for Research
4, Dostoevsky St., Moscow, 127473
O. V. Lovacheva
National Medical Research Center of Phthisiopulmonology and Infectious Diseases
Russian Federation
Russian Federation
Olga V. Lovacheva ‒ Doctor of Medical Sciences, Professor, Head Researcher
4, Dostoevsky St., Moscow, 127473
I. A. Vasilyeva
National Medical Research Center of Phthisiopulmonology and Infectious Diseases
Russian Federation
Russian Federation
Irina A. Vasilyeva ‒ Doctor of Medical Sciences, Professor, Director
4, Dostoevsky St., Moscow, 127473
References
1. Samoylova A.G. Effektivnost kompleksnogo lecheniya bolnykh tuberkulezom legkikh s shirokoy lekarstvennoy ustoychivostyu vozbuditelya i prichiny ee formirovaniya. Diss. dokt. med. nauk. [Efficacy of comprehensive treatment of pulmonary tuberculosis patients with extensive drug resistance and causes of its development. Doct. Diss.]. Moscow, 2017.
2. Meyssonnier V., Bui T.V., Veziris N., Jarlier V., Robert J. Rifampicin mono-resistant tuberculosis in France: a 2005-2010 retrospective cohort analysis. BMC Infect Dis., 2014, no. 14 (18), pp. 1-7. doi: 10.1186/1471-2334-14-18.
3. The end TB strategy: global strategy and targets for tuberculosis prevention, care and control after 2015- Geneva: World Health Organization, 2014,
4. World Health Organization. Treatment guidelines for drug-resistant tuberculosis. Geneva, World Health Organization, 2016.
5. WHO treatment guidelines for isoniazid-resistant tuberculosis: Supplement to the WHO treatment guidelines for drug-resistant tuberculosis ‒ Geneva: World Health Organization, 2018.
Review
For citations:
Burmistrova I.A., Vaniev E.V., Samoylova A.G., Lovacheva O.V., Vasilyeva I.A. Amplification of drug resistance against the background of inadequate chemotherapy for pulmonary tuberculosis. Tuberculosis and Lung Diseases. 2019;97(8):46-51. (In Russ.) https://doi.org/10.21292/2075-1230-2019-97-8-46-51
Views:
868
Email this article 